Survival in the SONIA Trial

Дата публикации: 18-06-2026 00:00:00

To the Editor We read with interest the report by Wortelboer et al evaluating sequencing strategies for cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6) inhibitors in hormone receptor–positive, ERBB2-negative advanced breast cancer. The authors concluded that delayed introduction of CDK4/6 inhibitors after initial endocrine therapy did not compromise overall survival (OS) compared with first-line use. While the SONIA trial provides important evidence regarding treatment sequencing, several aspects of the statistical framework warrant further clarification.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Survival in the SONIA Trial	0	8	18-06-2026
2	Survival in the SONIA Trial—Reply	0	5	18-06-2026
3	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
4	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
5	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
6	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
7	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
8	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
9	Error in Open Access License	0	5	18-06-2026
10	Three-Body Problem at Digital Frontiers	0	5	25-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.